celastrol has been researched along with Spondylitis, Ankylosing in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X; Wang, H; Zhao, X | 1 |
| Li, YK; Yang, XW; Yuan, SG; Zhang, P; Zou, YC | 1 |
2 other study(ies) available for celastrol and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Exploring hub pyroptosis-related genes, molecular subtypes, and potential drugs in ankylosing spondylitis by comprehensive bioinformatics analysis and molecular docking.
Topics: Ascorbic Acid; Computational Biology; Humans; Molecular Docking Simulation; Pyroptosis; Spondylitis, Ankylosing | 2023 |
Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro.
Topics: Adult; Cell Differentiation; Cell Proliferation; Dinoprostone; Dose-Response Relationship, Drug; Female; Fibroblasts; Hip Joint; Humans; Male; Osteogenesis; Pentacyclic Triterpenes; Spondylitis, Ankylosing; Structure-Activity Relationship; Triterpenes | 2016 |